This therapeutic approach targets FUS (Fused in Sarcoma) proteinopathy, a core pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS is an RNA-binding protein that normally resides in the nucleus but mislocalizes to cytoplasmic inclusions in a subset of ALS and FTD cases. This approach combines RNA-targeting strategies with proteostasis enhancement to reduce toxic FUS aggregates and restore nuclear function.
FUS is a 526-amino acid RNA-binding protein involved in RNA splicing, transport, and DNA repair. In ~5-10% of ALS cases and ~10% of FTD cases, FUS accumulates in cytoplasmic inclusions alongside TDP-43 pathology[1][2]. Mutations in the FUS gene (ALS6 locus) cause familial ALS, demonstrating that FUS dysfunction is disease-causing.
Key pathological features:
Primary Mechanism: Reduce FUS expression using RNA-targeting approaches (ASO, RNAi) or enhance FUS clearance through autophagy enhancement.
Secondary Mechanism: Target stress granule dynamics using small molecules that promote granule dissolution without blocking protective stress response.
Tertiary Mechanism: Nuclear import enhancement using nuclear localization signal (NLS) peptide conjugates or small molecule nuclear import enhancers.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | First-in-class mechanism targeting FUS proteinopathy distinct from TDP-43 approaches |
| Mechanistic Rationale | 8 | Strong genetic evidence (FUS mutations cause ALS6), pathology confirmed in sporadic cases |
| Addresses Root Cause | 8 | Targets protein aggregation at source rather than downstream effects |
| Delivery Feasibility | 6 | CNS delivery achievable via intrathecal ASO (proven in other ALS programs) |
| Safety Plausibility | 7 | Allele-specific targeting possible for mutant FUS sparing wild-type function |
| Combinability | 8 | Synergistic with TDP-43 targeted therapies, autophagy enhancers |
| Biomarker Availability | 7 | CSF FUS levels, pNfH as neurodegeneration marker, FUS PET ligands in development |
| De-risking Path | 7 | iPSC-derived neurons from FUS-ALS patients, FUS transgenic mouse models exist |
| Multi-disease Potential | 8 | ALS, FTD, and rare FUS-linked encephalopathies |
| Patient Impact | 8 | Addresses rapidly progressive motor neuron disease with high unmet need |
Total Score: 76/100
| Phase | Timeline | Cost | Key Milestones |
|---|---|---|---|
| Phase 1 | 12 months | $3-5M | Target validation, lead identification |
| Phase 2 | 14 months | $8-15M | IND-enabling studies, GLP toxicology |
| Phase 3 | 24 months | $25-40M | Clinical trials, registration |
| Total | 50 months | $36-60M |
Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009. ↩︎ ↩︎
Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009. ↩︎ ↩︎
Dormann D, Rodde R, Edbauer D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO Journal. 2010. ↩︎
Sharma A, Lyakhovetsky V, Ok A, et al. ALS-associated FUS mutations lead to mechanical cracking of RNA stress granules. Nature. 2016. ↩︎ ↩︎
Murray DT, Kato M, Lin Y, et al. Structure of FUS protein fibrils and its relevance to self-assembly and phase separation. Cell. 2018. ↩︎ ↩︎
Tibshirani M, Tradewell ML, Mattedi K, et al. Cytoplasmic accumulation of FUS in motor neurons is sufficient to cause ALS-like phenotypes in mice. Acta Neuropathologica. 2016. ↩︎ ↩︎ ↩︎
Monahan Z, Shewmaker F, Pandey UB. Stress granules in ALS and FTD: emerging mechanistic insights. Journal of Pathology. 2016. ↩︎